**Lay Report of Important Outcomes**

We successfully obtained IRB approval for the first known functional precision medicine trial for metastatic breast cancer. To date, we have enrolled 5 patients. 4 of them remained eligible to continue study. Thus, we are almost 1/3 of the way to our accrual goal of 15 patients; the study is ongoing. We have continued to optimize our functional precision medicine pipeline with each case, which is a key aspect of this novel feasibility study. We look forward to reporting final results at the end of the trial.